
But industry body warns sector “faces real challenges” from austerity and global competition
Europe’s pharmaceutical companies increased their spending on R&D by about €1.8 billion between 2020 and 2021, according to new figures.
The European Federation of Pharmaceutical Industries and Associations estimated that companies in the EU, Norway, Switzerland and UK spent €41.5bn on R&D in 2021 compared with €39.7bn in 2020. In 2010, the figure was €27.9bn, Efpia said.